| This week's sponsor is Premier Research. | |  | Atopic Dermatitis: Where Do We Go From Here?
Improved understanding of atopic dermatitis is revealing new insights and treatment options. Get current by downloading our white paper examining these exciting and emerging therapies. Premier Research. It's what we do. Best. |
Today's Rundown Featured Story | | | Tuesday, December 19, 2017 Genentech has entered into a multitarget drug discovery deal with DiCE Molecules. The Roche unit is handing over an upfront fee and committing to milestones to apply DiCE’s small molecule platform to targets of interest. |
|
|
Top Stories Tuesday, December 19, 2017 Furor erupted when reports emerged that the CDC was banning certain words and phrases from official budget documents. The agency's director denied the the existence of a ban, saying the guidelines were discussed in a budget-related meeting and should not be construed as "overall guidance." Tuesday, December 19, 2017 Array and Pfizer will collaborate on a phase 1b trial investigating combinations of Array's binimetinib and Pfizer's PARP inhibitor talazoparib and anti-PD-L1 med avelumab in non-small cell lung cancer and pancreatic cancer. Monday, December 18, 2017 Randomized, placebo-controlled clinical trials are the most complex step in the development of new drugs. A contributor to trial failure is the increased rate of placebo response, which is now historically high. How can these trends be reversed? Tuesday, December 19, 2017 Germany’s Boehringer Ingelheim has entered into a deal with Evox Therapeutics, its second with a U.K.-based biotech in as many days. Monday, December 18, 2017 When a biologics company prepares to launch a new product, it must forecast the capacity it will need. Learn how to mitigate risks by developing a manufacturing strategy that will accommodate a forecast range and allow you to adapt as better data becomes available. Tuesday, December 19, 2017 Roche has entered into a neurological and developmental disorder drug discovery pact with Confo Therapeutics. The agreement gives Roche a potential source of small molecule agonists of an undisclosed G-protein coupled receptor. Tuesday, December 19, 2017 Christina Waters, Ph.D., founder and CEO of pediatric rare disease nonprofit Rare Science, joined genomics firm WuXi NextCODE as senior VP, focusing on bolstering its rare disease programs. Tuesday, December 19, 2017 Respicardia has rounded up $58.5 million to commercialize its sleep apnea device in the U.S. The Zoll Medical-led round comes two months after Respicardia secured FDA clearance to market its implantable neurostimulation system. Resources Sponsored by: Reprints Desk SO CLOSE AND YET SO FAR. Is that how many documents seem to you? Getting what you want—when, where, and how you want it—can be a real pain. That’s why we created this concise guide to getting around the obstacles that stand between you and the information your organization needs. Download the whitepaper to learn more. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Deloitte Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Sponsored by: Veeva Systems Read Deloitte Consulting's whitepaper on the value of a holistic RIM capability, covering the potential cost savings and revenue gains from doing RIM right. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. | 
